1.20
전일 마감가:
$1.21
열려 있는:
$1.22
하루 거래량:
2.33M
Relative Volume:
4.71
시가총액:
$54.85M
수익:
-
순이익/손실:
$-40.56M
주가수익비율:
-1.0256
EPS:
-1.17
순현금흐름:
$-35.28M
1주 성능:
-7.69%
1개월 성능:
-25.93%
6개월 성능:
-17.24%
1년 성능:
-70.07%
Pds Biotechnology Corporation Stock (PDSB) Company Profile
명칭
Pds Biotechnology Corporation
전화
800-208-3343
주소
303A COLLEGE ROAD EAST, PRINCETON
PDSB을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
PDSB
Pds Biotechnology Corporation
|
1.20 | 59.42M | 0 | -40.56M | -35.28M | -1.17 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2022-11-01 | 개시 | B. Riley Securities | Buy |
2021-06-28 | 개시 | Cantor Fitzgerald | Overweight |
2020-11-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
2020-05-27 | 개시 | Alliance Global Partners | Buy |
2020-03-09 | 개시 | Noble Capital Markets | Outperform |
2019-10-24 | 개시 | Chardan Capital Markets | Buy |
모두보기
Pds Biotechnology Corporation 주식(PDSB)의 최신 뉴스
PDS Biotechnology Corporation Stock Analysis and ForecastMarket-crushing profits - Jammu Links News
What drives PDS Biotechnology Corporation stock priceFree Stock Market Knowledge Sharing - Jammu Links News
Why PDS Biotechnology Corporation stock attracts strong analyst attentionFree Stock Market Knowledge Sharing - Newser
What makes PDS Biotechnology Corporation stock price move sharplyFree Day Trading Recommendations - Newser
How PDS Biotechnology Corporation stock performs during market volatilityLow Risk Consistent Winners - Newser
PDS Biotechnology stock advances as Phase 2 trial meets expansion criteria - Investing.com
PDS Biotechnology completes recruitment for stage one of colorectal cancer trial - Yahoo Finance
PDS Biotechnology Corporation Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results - MarketScreener
PDS Biotechnology stock rises after trial meets criteria for expansion By Investing.com - Investing.com Nigeria
PDS Biotechnology stock rises after trial meets criteria for expansion - Investing.com Australia
PDS Biotech's PDS01ADC: A Breakthrough in Cytokine Therapy for Metastatic Colorectal Cancer - AInvest
PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results - The Manila Times
PDS Biotech Achieves Crucial Phase 2 Milestone: Colorectal Cancer Drug Shows Promising Early Results - Stock Titan
PDS Biotechnology (PDSB) Retains "Buy" Rating with Price Target Unchanged | PDSB Stock News - GuruFocus
PDSB’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Transcript : PDS Biotechnology CorporationSpecial Call - MarketScreener
PDS Biotechnology holds a conference call - TipRanks
PDS Biotechnology (NASDAQ:PDSB) Stock Rating Lowered by Wall Street Zen - Defense World
HC Wainwright Issues Pessimistic Estimate for PDSB Earnings - Defense World
PDS Biotechnology Co. (NASDAQ:PDSB) Shares Sold by Millennium Management LLC - Defense World
Two Sigma Investments LP Raises Stock Holdings in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
PDS Biotechnology (NASDAQ:PDSB) Receives Buy Rating from HC Wainwright - Defense World
PDS Biotech expands equity incentive plan By Investing.com - Investing.com Canada
PDS Biotech expands equity incentive plan - Investing.com
PDS Biotechnology Approves Equity Plan Amendment at Meeting - TipRanks
# H.C. Wainwright maintains Buy rating on PDS BIOTECHNOLOGY stock - Investing.com
# H.C. Wainwright maintains Buy rating on PDS BIOTECHNOLOGY stock By Investing.com - Investing.com UK
PDSB Biotechnology's Virtual Event to Discuss Advances in HPV16-Positive HNSCC | PDSB Stock News - GuruFocus
PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC - The Manila Times
PDS Biotechnology Corporation to Host Webinar on HPV16-Positive HNSCC and Merck KN-689 Study - Nasdaq
Jane Street Group LLC Invests $58,000 in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
Northern Trust Corp Trims Stock Holdings in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
PDS Biotech reports steady survival rates in HPV16-positive HNSCC trial By Investing.com - Investing.com South Africa
2 Biopharmaceutical Stocks Focused on Cancer That Wall Street Predicts Will More Than Double - inkl
Take the Zacks Approach to Beat the Markets: StoneCo, Axon, Intuit in Focus - TradingView
PDSB: PDS Biotechnology Releases Promising Results from Versamune HPV Studies | PDSB Stock News - GuruFocus
PDS Biotechnology Publishes Versamune® HPV Abstracts at ASCO - TipRanks
PDS Biotech reports steady survival rates in HPV16-positive HNSCC trial - Investing.com India
Clinical Trial Breakthrough: PDS Biotech Achieves 30-Month Survival in Advanced Head and Neck Cancer Patients - Stock Titan
PDS Biotechnology files to sell 9.82M shares of common stock for holders - MSN
PDS Biotechnology (PDSB) Announces Plan to Offer 9.82 Million Sh - GuruFocus
PDS Biotechnology (PDSB) Plans Sale of 9.82 Million Shares | PDS - GuruFocus
PDS Biotechnology (PDSB) Announces Plan to Offer 9.82 Million Shares - GuruFocus
PDS Biotechnology (PDSB) Plans Sale of 9.82 Million Shares | PDSB Stock News - GuruFocus
Wall Street Zen Upgrades PDS Biotechnology (NASDAQ:PDSB) to “Hold” - Defense World
PDS Biotechnology Corporation (PDSB)’s Versamune HPV Surpasses Survival Benchmarks in Recurrent Head and Neck Cancer Trial - Insider Monkey
Q2 EPS Estimates for PDS Biotechnology Raised by B. Riley - Defense World
PDS Biotech reports extended survival in HPV cancer study - Investing.com Australia
PDS Biotech reports extended survival in HPV cancer study By Investing.com - Investing.com India
Pds Biotechnology Corporation (PDSB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Pds Biotechnology Corporation 주식 (PDSB) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Glover Stephen C. | Director |
Feb 28 '25 |
Buy |
1.66 |
15,061 |
25,001 |
78,851 |
자본화:
|
볼륨(24시간):